Lymphoma Therapeutics Section
Medical Oncology Branch and Affiliates
Metabolism Branch and the Laboratory of Molecular Biology
Mission
The mission of the Lymphoma Therapeutics Section is to advance the treatment and the understanding of lymphoproliferative disorders. A primary goal is to investigate and develop innovative strategies involving novel targets, pharmacodyamics, pharmacogenomics and reversal of drug resistance. Another primary goal is to investigate the clinical and biological natural history of lymphoproliferative disorders in an effort to define pathobiology, novel therapeutic targets, and mechanisms of drug resistance. These efforts are integrated in a translational approach that involves close collaboration between the laboratory and clinic.
Overview
The Lymphoma Therapeutic Section comprises attending physicians, nurse practitioners, and research nurses who provide clinical care for patients enrolled on clinical protocols. The group has several disease areas of interest that focus on Aggressive B- and T-cell lymphomas, Indolent B-cell lymphomas, and chronic leukemias including chronic lymphocytic leukemia and Hairy cell leukemia. The section also has an interest and expertise in lymphoproliferative diseases in the setting of immunodeficieny including lymphomatoid granulomatosis, EBV-associated lymphoproliferative disorders, and HIV associated lymphomas. The group is dedicated to conducting translational studies on the biology and treatment of these diseases. Many of the protocols in this section have arisen from discoveries in the laboratory. The group collaborates closely with and supports several laboratories and programs within the NIH campus, maintaining close and integral bench-bedside links.
The Research Team
Wyndham Wilson, M.D., Ph.D.
Lymphoma Therapeutics Section
Metabolism Branch
Medical Oncology Branch and Affiliates, CCR, NCI
Dr. Wyndham H. Wilson received his B.A. and M.S. in biology from Stanford University in 1975. In 1981, he received his Ph.D. in neurobiology and M.D. from Stanford, and he completed residency training in internal medicine at Stanford in 1984. From 1984 to 1987, he was a clinical associate in the Medicine Branch, NCI, where he completed a fellowship in medical oncology. Dr. Wilson was special assistant to the director, Division of Cancer Treatment, NCI, from 1988 to 1995. In 1995, he joined the former Medicine Branch as a senior oncologist.
Read more
Robert Kreitman, M.D.
Lymphoma Therapeutics Section
Laboratory of Molecular Biology
Medical Oncology Branch and Affiliates, CCR, NCI
Dr. Robert J. Kreitman received his M.D. from Ohio State University in 1985 and obtained his internal medicine residency training at Duke University from 1985 to 1988. He received his medical oncology fellowship training at the NIH from 1988 to 1991, has been working in the immunotoxin field since 1989, and has been directing clinical trials with immunotoxins since 1996.
Read more
John Morris, M.D.
Lymphoma Therapeutics Section
Metabolism Branch
Medical Oncology Branch and Affiliates, CCR, NCI
Dr. John C. Morris received his B.A. with honors in biology from Queens College (CUNY) in Flushing, N.Y., in 1978, and his M.D. degree in 1982 from the Upstate Medical Center College of Medicine (SUNY) in Syracuse, N.Y. He completed a residency in Internal Medicine and a clinical fellowship in Medical Oncology at the Mount Sinai Hospital in New York City. He served as Chief Medical Resident and subsequently as Assistant Professor of Medicine and Neoplastic Diseases at Mount Sinai. Dr. Morris did a post-doctoral fellowship in the Clinical Gene Therapy Branch of the National Human Genome Research Institute from 1995 to 1999.
Read more
John Janik, M.D.
Lymphoma Therapeutics Section
Metabolism Branch
Medical Oncology Branch and Affiliates, CCR, NCI
Dr. John E. Janik received his M.D. from the Ohio State University College of Medicine in 1977 and completed clinical training in internal medicine at Baylor College of Medicine Affiliated Hospitals and hematology/oncology training at Case Western Reserve University. He joined NCI in 1989 at the Biological Response Modifiers Program in Frederick, Md. In 1999 he was appointed Co-Director, Clinical Trials Team, in the Metabolism Branch.
Read more
Kieron Dunleavy, M.D.
Lymphoma Therapeutics Section
Metabolism Branch
Medical Oncology Branch and Affiliates, CCR, NCI
Dr. Kieron Dunleavy was appointed Attending Staff Clinician at NCI in March 2006. He graduated from University College Dublin Medical School in 1994 and completed his residency and fellowship training at the Mater and St. James's Hospitals, Dublin, before coming to NCI in 2002 for a fellowship in Medical Oncology. Having completed his fellowship in February 2006, he was appointed to the position of Investigator/Attending Physician with the Metabolism Branch.
Read more
Adrian Weistner, M.D., Ph.D.
Hematology Branch
National Heart Lung and Blood Institute (NHLBI)
Dr. Adrian Wiestner's current projects at NHLBI address pathogenic mechanisms in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and aim at the identification and validation of therapeutic targets in these diseases. As a Clinical Fellow for the Metabolism Branch at NCI from 2001 to 2004, Dr. Wiestner also participated in studies on CLL and MCL, as well as those on multiple myeloma. He received his medical degree from the University of Basel Medical School, Basel, Switzerland, in 1991 and is also a 1997 graduate of the M.D./Ph.D. Program, Biozentrum, University of Basel, Switzerland.
Dr. Wiestner also works closely with NCI's Lymphoma team and serves as the scientific study chair on two protocols in CLL and MCL. His laboratory uses gene expression profiling and related molecular analyses to study the underlying disease mechanisms and to investigate how modern cancer therapies kill the malignant cells.
Read more
Back to Top
